Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.

Abstract: Compounds of general formula (I) are described. Also described, is the use of such compounds in pharmaceutical compositions for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmologic disorders, in particular), or in cosmetic compositions.

Abstract: A self-foaming composition is described that includes ivermectin, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and ivermectin being present in the composition A, in the composition B, or simultaneously in the two compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.

Abstract: The invention relates to a method for determining in vitro release rate of at least one active principle ingredient from at least one semisolid form.

Abstract: The present invention is related to a pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin.

Abstract: Novel compounds, synthesis methods and use of the same in medicine and in cosmetics are disclosed. Also disclosed, are novel compounds and ligands that modulate RARs.

Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a backbone diol function of a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.

Abstract: A new hydrogel made of double crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Double crosslinked glycosaminoglycans, one linkage via two ether bonds with a hydroxyl group of each of two glycosaminoglycans and another linkage via an alkoxyboronate ester anion formed between a boronate hemiester grafted to one of the glycosaminoglycans and a diol function of to the other glycosaminoglycan. The diol function may be a backbone diol function or a diol portion of a diol functional moiety grafted the other glycosaminoglycan.

Abstract: The invention relates to new compounds of the general formula (I): as well as the use thereof in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, in particular), or in the use of cosmetic compositions.

Abstract: The present invention relates to a novel process for preparing enantiomerically pure compounds of N-(pyrid-4-yl)-2-hydroxyalkylamide type corresponding to the general formula (C) below: and also to processes for preparing the reaction intermediates used in this synthesis, said intermediates having the general formulae (A) and (B) below:

Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.

Abstract: The use of compounds in the treatment of skin disorders is described. In particular, use of a compound of formula (I): or one of its pharmaceutically acceptable salts, solvates or hydrates in the preparation of a medicament to treat skin pathologies is described.

Abstract: The present invention relates to a novel process for preparing enantiomerically pure compounds of N-(pyrid-4-yl)-2-hydroxyalkylamide type corresponding to the general formula (C) below: and also to processes for preparing the reaction intermediates used in this synthesis, said intermediates having the general formulae (A) and (B) below:

Abstract: The invention relates to a method for determining in vitro release rate of at least one active principle ingredient from at least one semisolid form.

Abstract: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C.

Abstract: Methods, compositions and products for preventing skin tumor formation or inhibiting the development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an ? adrenergic receptor agonist, such as brimonidine.

Abstract: A combination includes a child-resistant package and a collapsible tube removably positionable therein. A sidewall of a body of the package has an interior surface and an opposing exterior surface. A cavity is defined by the body. An opening is positioned proximate an open first end of the body. A bottom wall is positioned proximate an open second end of the body. A cap is removably mounted onto at least a portion of the first end of the body. The collapsible tube is surrounded by the body, the bottom wall and the cap when the cap is mounted onto at least a portion of the first end of the body. The collapsible tube includes a generally flexible housing defining a cavity for holding a substance to be dispensed from the housing. A closure is removably mounted onto the housing.

Abstract: A combination includes a container having a body with a first end and a second end. The body defines a cavity for holding contents to be dispensed from the container. An actuator is positioned proximate to the first end of the body. The actuator is operatively connected to the cavity to allow the contents to be dispensed therefrom. At least two diametrically opposed first fastening members are positioned on or in the body. A device has a generally open first end, a generally open second end, and a sidewall extending therebetween. The device is removably mountable onto the body of the container. At least two diametrically opposed second fastening members are positioned on or in an interior surface of the sidewall. Each second fastening member engages at least a portion of one of the first fastening members of the container when the device is mounted onto the container.

Abstract: A method is described for the synthesis of 4-piperidin-4-yl-benzene-1,3-diol of the following formula (I): and the pharmaceutically acceptable salts thereof.

Abstract: The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.